Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
CRAIG BROWN: The killer who wants to be Donald Trump's running mate
In the world of publishing, it has become fashionable for books by politicians to carry urgent, wor2024-05-01Titanic 'door' prop that kept Rose alive sells for more than $1m
The Titanic movie scene which divided fans as to whether Rose and Jack could both fit on the wood pa2024-05-01Gazans return to scenes of devastation in Khan Younis
Palestinians walk past destroyed residential buildings in Qatari-funded Hamad City, following an Isr2024-05-01Biden administration imposes first
The Biden administration on Wednesday finalized strict limits on certain so-called “forever chemical2024-05-01- NEW YORK (AP) — Walmart said Tuesday it is launching its biggest store-label food brand in 20 years2024-05-01
Chris Hipkins says sick children shouldn't be at school
Photo: RNZ / Angus Dreaver2024-05-01
atest comment